Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
user
  1. Dashboard
  2. My Profile
  3. My Address
  4. My Orders
  5. Acro Membership
Login Register
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP Cytokines Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
There is no goods in the shopping cart !
My Cart|Secure Checkout
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > GP120

GP120

Brief Information

Name:Transmembrane protein PVRIG
Target Synonym:PVRIG,PVR Related Immunoglobulin Domain Containing,CD112 Receptor,Poliovirus Receptor-Related Immunoglobulin Domain-Containing Protein,Poliovirus Receptor Related Immunoglobulin Domain Containing,Nectin-2 Receptor,C7orf15,CD112R,Transmembrane Protein PVRIG,MGC2463
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Phase 2 Clinical

Product Inquiry

* We couldn't find what you're looking for. You can let us help by filling the form below. Our tech team will get back to you shortly.
* This form is only used to collect product demand consultation. All the information will be kept strictly confidential.
Product inquiry collection form
*
*
*
*
*
*
*
*
*
ACRO Quality

Synonym Name

GP120,GP120-CN54

Background

Human Immunodeficiency Virus (HIV) can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to viruses found in chimpanzees and gorillas living in western Africa. HIV-2 is related to viruses found in sooty mangabeys. HIV-1 viruses may be further divided into groups. The HIV-1 group M viruses predominate and are responsible for the AIDS pandemic. Some of the HIV-1 group M subtypes are known to be more virulent or are resistant to different medications. HIV-2 viruses are thought to be less virulent and transmissible than HIV-1 M group viruses. Envelope glycoprotein GP120 (or gp120) is the name of the glycoprotein which forms the spikes sticking out of a HIV virus particle. gp120 is essential for virus entry into cells as it plays a vital role in seeking out specific cell surface receptors for entry. Three gp120s, bound as heterodimers to a transmembrane glycoprotein, gp41, are thought to combine in a trimer to form the envelope spike, which is involved in virus-cell attachment. One half of the molecular weight of gp120 is due to the carbohydrate side chains (the "glyco-" in "glycoprotein"). These are sugar residues which form something almost like a sugar "dome" over the gp120 spikes. This dome prevents gp120 from being recognised by the human immune response. As the HIV virus and the human CD4 cell come together, the gp120 binding site "snaps open" at the last minute.The glycoprotein gp120 is anchored to the viral membrane, or envelope, via non-covalent bonds with the transmembrane glycoprotein, gp41. It is involved in entry into cells by binding to CD4 receptors, particularly helper T-cells. Binding to CD4 is mainly electrostatic although there are van der Waals interactions and hydrogen bonds.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
COM-701 COM-701 Phase 2 Clinical Compugen Ltd Solid tumours; Head and Neck Neoplasms; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms Details
PM-1009 PM1009 Phase 2 Clinical Liver Neoplasms; Solid tumours; Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular Details
SIM-0348 SIM-0348 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Solid tumours; Neoplasms Details
GSK-4381562 SRF-813; GSK-4381562; GSK-4381562A; GSK4381562A Phase 1 Clinical Surface Oncology Inc Solid tumours; Neoplasms Details
NM1F NM1F; TGI-2 Phase 1 Clinical Hefei TG ImmunoPharma Co Ltd Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma Details
SHR-2002 SHR-2002 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Neoplasms Details
JS-009 JS009; TAB009; JS-009 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Neoplasms Details
COM-701 COM-701 Phase 2 Clinical Compugen Ltd Solid tumours; Head and Neck Neoplasms; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms Details
PM-1009 PM1009 Phase 2 Clinical Liver Neoplasms; Solid tumours; Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular Details
SIM-0348 SIM-0348 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Solid tumours; Neoplasms Details
GSK-4381562 SRF-813; GSK-4381562; GSK-4381562A; GSK4381562A Phase 1 Clinical Surface Oncology Inc Solid tumours; Neoplasms Details
NM1F NM1F; TGI-2 Phase 1 Clinical Hefei TG ImmunoPharma Co Ltd Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma Details
SHR-2002 SHR-2002 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Neoplasms Details
JS-009 JS009; TAB009; JS-009 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap